MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Cara Therapeutics Company Profile (NASDAQ:CARA)

Consensus Ratings for Cara Therapeutics (NASDAQ:CARA) (?)
Ratings Breakdown: 6 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $23.83 (288.80% upside)

Analysts' Ratings History for Cara Therapeutics (NASDAQ:CARA)
Show:
DateFirmActionRatingPrice TargetActions
4/23/2016Piper JaffrayReiterated RatingOverweight$23.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/20/2016Cantor FitzgeraldReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/21/2016Needham & Company LLCReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/12/2016Janney Montgomery ScottReiterated RatingBuy$23.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/29/2016LaidlawLower Price TargetBuy$30.00 -> $17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/11/2015Canaccord GenuityReiterated RatingBuy$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2015MLV & Co.Initiated CoverageBuy$26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/9/2014Summer StreetInitiated CoverageBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/3/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha